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Abstract
The Protein Data Bank (PDB) contains more than 135 000 entries today. From
these, relatively few amyloid structures can be identified, since amyloids are
insoluble in water. Therefore, mostly solid state NMR-recorded amyloid struc-
tures are deposited in the PDB. Based on the geometric analysis of these de-
posited structures we have prepared an automatically updated webserver, which
generates the list of the deposited amyloid structures, and, additionally, those
globular protein entries, which have amyloid-like substructures of a given size
and characteristics. We have found that applying only the properly chosen ge-
ometric conditions, it is possible to identify the deposited amyloid structures,
and a number of globular proteins with amyloid-like substructures. We have
analyzed these globular proteins and have found proofs in the literature that
many of them are known to form amyloids more easily than many other glob-
ular proteins. Our results relate to the method of (Stankovic, I. et al. (2017):
Construction of Amyloid PDB Files Database. Transactions on Internet Re-
search. 13 (1): 47-51), who have applied a hybrid textual-search and geometric
approach for finding amyloids in the PDB. If one intends to identify a subset of
the PDB for some applications, the identification algorithm needs to be re-run
periodically, since in 2017, on average, every day 30 new entries were deposited
in the data bank. Our webserver is updated regularly and automatically, and
the identified amyloid- and partial amyloid structures can be viewed or their
list can be downloaded from the site https://pitgroup.org/amyloid.
Introduction
The Protein Data Bank (PDB) is a permanently developing public resource
of spatial structures of proteins and nucleic acids [1]. Today the database con-
tains more than 135,000 structures. The geometric properties of these molecules
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can be analyzed by bioinformatical tools, and one may infer significant new re-
lations in these very complex macromolecular structures through these analyses
[2, 3, 4, 5, 6, 7, 8, 9].
In the present contribution, we are interested in the amyloid structures in
the Protein Data Bank. Amyloids are misfolded protein aggregates, which are
present in numerous structures in biology, including
• the cellular surface of several microorganisms [10, 11], having a role in
host-pathogen interaction;
• the silkmoth chorion and some fish choria, forming protective films [12];
• the immune system of certain insects, helping the encapsulation of the
intruders [13];
• in the healthy human pituitary secretory granules, for storing peptide
hormones [14];
• in human amyloidoses and several neurodegenerative diseases [15].
Amyloid structures sometimes show prion-like infective properties [15, 16,
17]. Cerebral β-amyloid plaques have been considered biomarkers of the
Alzheimer’s disease for a long time [18, 19, 20, 21]; but more recently, their
validity is challenged by several authors [22, 23, 24].
Amyloid formation mechanisms are reviewed in [25, 26]. Amyloid fibers
are formed from parallel β-sheets, with hydrogen bonds between the parallel
strands. It is widely accepted that amyloid formation requires the presence of a
nucleus or a seed of amyloid-forming segments with exposed edges of the β-sheet
structures [27, 28, 25, 26].
Since amyloid fibers are insoluble in water until the very recent years there
were no high-resolution structures deposited in the RCSB Protein Data Bank
(PDB) [1]. Today one can find several dozens of atomic resolution amyloid
structures in the PDB, and this dataset opened up the possibility of the analysis
and the data mining of the properties of these misaligned proteins, using their
high-resolution spatial structure.
The first step in this direction is the identification of the amyloid structures
in the PDB.
Amyloid- and amyloid-precursor molecules were collected and predicted us-
ing protein-sequencing data in numerous articles (e.g., in the AMYPdb resource
[29], or in [30]). We are interested in the analysis of the spatial protein structures
for finding amyloid and amyloid-precursor molecules, rather than the analysis
of residue-sequence properties of proteins of unknown three-dimensional struc-
tures.
In the remarkable work [31] the authors screened the Protein Data Bank for
amyloid structures, by applying the following procedure:
(i) By textual search, those PDB entries were selected, which contain the
words “amyloid” or any of other 38 words, describing amyloid precursors;
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(ii) Helical structures, identified by torsion angles, were thrown out;
(iii) Parallel, near-linear fragments of length at least 4 residues were identified;
structures without these fragments were also thrown away.
In the present work, we prepare an automatically updated list of amyloid
and potentially amyloidogenic structures from the PDB, with applying only the
geometric properties of β-sheets; consequently, we do not use any textual search,
referring to the annotations of the PDB entries.
By this choice, we intend to identify not only the aggregated amyloid entries
and known precursors, but also those globular proteins, which contain small,
locally amyloid-like substructures. We assume that these globular proteins may
also be amyloidogenic ones, i.e., they can more easily turn into amyloid fibers
than globular proteins without these structural elements.
Since the Protein Data Bank grows very quickly – in 2017, every day, on the
average, 30 new structures were deposited – we need to construct an automati-
cally updated web server, which periodically examines the new PDB entries and
includes the newly deposited amyloid and potentially amyloidogenic structures.
Consequently, our list does not give a snapshot of the amyloid structures in the
PDB at a given time as other efforts but rather presents a live list of these struc-
tures. Our online resource is available at https://pitgroup.org/amyloid/.
Discussion and Results
Amyloid structures
We have found that our list at https://pitgroup.org/amyloid/ contains
all amyloid structures with at least two polypeptide chains, which are listed
in [31]. For example, the classical amyloid structures of 2KIB, 2N0A, 5KO0,
2LBU, 2LMN are all present in the list.
Possibly Amyloidogenic Structures
Here we review some non-amyloid proteins which were found by our screen-
ing algorithm, and which are listed at https://pitgroup.org/amyloid/. We
also give literary evidence showing links to the amyloid formation of these
molecules. These findings witness the power of our algorithm, but clearly, we
cannot review here the more than 500 structures, presented on the webpage
https://pitgroup.org/amyloid/.
1HCN: Human chorionic gonadotropin (hCG), Fig. 1, panel A. It is a placenta-
produced human hormone, applied in numerous pregnancy tests and in
legal and illegal drug products, including physical performance enhancing
and weight-loss preparations. It is reported to increase β-amyloid levels in
rats [32] and to increase β-cleavage of an amyloid-precursor protein [33].
Protein hCG also has a role in amyloid β precursor protein expression
and modulation in human cells [34], and in protein folding regulation in
endoplasmic reticulum [35]. We believe that these roles of hCG are closely
related to particular geometric properties of its parallel β-sheets.
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1BSF: Thymidylate synthase A (TS) from Bacillus subtilis. Thymidylate syn-
thase has an important role in DNA synthesis, whose aggregational proper-
ties were studied for a long time [36]. The human TS is a primary target of
cancer chemotherapy, most importantly by 5-fluorouracil, a strong-binding
TS inhibitor, applied widely in colon-, esophageal-, stomach-, pancreatic-,
breast- and cervical cancers. On Fig. 1., panel B, it is clearly visible that
the parallel beta-sheets are hidden in the dimeric structure. As it is shown
in [37], TS also has a monomeric form with distinct function, and the
dimeric and the monomeric forms have an equilibrium in humans. There-
fore, the hidden β-sheets in the monomeric form may become accessible
and may play a role in aggregation processes.
3FJ5: Tyrosine kinase c-Src (Fig. 1, panel C) has a role in MAP kinase pathway,
and in the development of breast cancers in animals and humans [38, 39].
It is shown that the SH3 domain of this protein aggregates to form amyloid
fibrils at mild acid pHs in [40]. Sources [41, 42] suggest that amyloid
associated microgliosis is strengthened by tyrosine kinase c-Src activity.
It is also noted that MAP kinase signaling cascade dysfunction specific to
Alzheimer’s disease in fibroblasts [43].
2OCT: Stefin B (Cystatin B) tetramer (Fig. 1, panel D) is an intracellular thiol
protease inhibitor. It is known to form amyloid fibrils in vitro [44], its role
in amyloidogenesis is detailed in [45] and [46].
Materials and Methods
Here we describe the selection method, which generates the Extended Amy-
loid List at https://pitgroup.org/amyloid/.
In contrast with [31], we did not make any selection through textual search
in the annotation fields of the PDB files. Instead of that, we have attempted
to collect the minimal set of geometric rules, which already return the amy-
loids found in [31], plus novel, globular proteins with possibly amyloidogenic
substructures.
The following rules are applied:
(i) For finding parallel β-sheets: The authors of [31] selected parallel chain
segments by requiring the distance-difference between the closest Cα atoms
of the fragment to be less than 1.5 A˚. Instead of this condition, we have ap-
plied a bound to the standard deviation σ between the closest Cα atoms
of the fragment to be less than 1.5 A˚. We think that this approach is
more tolerant to singular, random errors in the structure, while it is strict
enough for characterizing the parallel polypeptide chains in the amyloid
structures. More technically, our condition can be re-phrased as follows:
let us consider two separate chains of the structures, A and B, both iden-
tified as β-sheets. Next, we compute the array C(A)dist, which contains
the minimum distance for every Cα atom of chain A from the closest Cα
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that is located in chain B. Next, we identify the maximal sub-chains F
of A, satisfying σ(C(F )dist) ≤ 1.5, while every distance in vector C(F )dist
are required to be between 2 and 15 A˚.
(ii) Excluding structures with large curvature: The authors of [31] excluded
helical structures from consideration. We apply a locally verifiable angular
condition for the fragments F as follows: Fragment F , which satisfies the
conditions in (i), needs also to satisfy the condition that the angles of
each three consecutive Cα atoms, averaged for the fragment F , need to
be between 110◦ and 180◦. In other words, these angles, on the average,
should be obtuse angles between 110◦ and 180◦.
(iii) Condition for the minimum length of parallel fragments: len(F ) ≥
len(chainA)
7 where F denotes the same as in (i), and len(X) denotes the
length of chain X, measured in residues.
The specific parameters for the conditions above were selected for including
all multi-chain amyloid structures that were also found in [31]. We do not aim to
find amyloid-like structures containing only one single polypeptide chain since
the amyloid structures contain a large number of approximately parallel fibers,
each consisting of different chains. While the Protein Data Bank contains partial
amyloid structures with one single chain (e.g., 1HZ3), these structures will not
be listed within our results, since they lack the characteristic property of nearly
parallel, distinct polypeptide chains. The search for distinct parallel chains is
useful for disallowing single chains with long parallel subsections, for example,
beta-barrel structures, like the bacterial porin structure 4RLC. Since amyloid
aggregates always consist of a large number of distinct, approximately parallel
polypeptide chains, our condition is not restrictive.
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Figure 1: Protein structures 1HCN, 1BSF, 3FJ5 and 2OCT, with partial amyloid-like sub-
structures. All of these entries are documented as amyloidogenic in the literature.
Conclusions
We have demonstrated the validity of three geometric structural selection
rules, which identify amyloid fibrils and plaques in the Protein Data Bank.
Additionally, these rules find non-amyloid soluble proteins, among which we
have identified several amyloidogenic ones by scanning the literature. We believe
that the great majority of the soluble proteins in the list show also — mostly
still undocumented — amyloidogenic properties.
Data availability
The automatically updated web page is available at https://pitgroup.
org/amyloid/. The page contains the list of the PDB entries found by our
program, each entry is given in the graphical form, hyperlinked to the structures
at the RCSB PDB site https://www.rcsb.org/pdb.
The Python source code of the software program, which generates the
PDB Amyloid list is available at http://uratim.com/amyloid/amyloid_pit.
zip.
The page https://pitgroup.org/amyloid/ contains not only the graphical
representation of the proteins found but also a list of their PDB codes at https:
//pitgroup.org/apps/amyloid/amyloid_list.
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